These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7905192)

  • 1. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects.
    Svensson K; Eriksson E; Carlsson A
    Neuropharmacology; 1993 Oct; 32(10):1037-45. PubMed ID: 7905192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
    Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
    Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.
    Svensson K; Ekman A; Piercey MF; Hoffmann WE; Lum JT; Carlsson A
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):263-74. PubMed ID: 1683686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of presynaptic 5-HT
    Mombereau C; Arnt J; Mørk A
    Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
    Rasmussen K; Hsu MA; Noone S; Johnson BG; Thompson LK; Hemrick-Luecke SK
    Schizophr Bull; 2007 Nov; 33(6):1291-7. PubMed ID: 17660489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol.
    Hillegaart V; Ahlenius S
    Pharmacol Toxicol; 1987 May; 60(5):350-4. PubMed ID: 3615345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat.
    Ahlenius S; Wijkström A
    Eur J Pharmacol; 1992 Nov; 222(1):69-74. PubMed ID: 1361441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.
    Jackson DM; Ross SB; Larsson LG
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Oct; 340(4):355-65. PubMed ID: 2573842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early life stress causes refractoriness to haloperidol-induced catalepsy.
    Marrocco J; Mairesse J; Bucci D; Lionetto L; Battaglia G; Consolazione M; Ravasi L; Simmaco M; Morley-Fletcher S; Maccari S; Nicoletti F
    Mol Pharmacol; 2013 Aug; 84(2):244-51. PubMed ID: 23716620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
    Prinssen EP; Colpaert FC; Koek W
    Eur J Pharmacol; 2002 Oct; 453(2-3):217-21. PubMed ID: 12398907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
    Meltzer LT; Christoffersen CL; Corbin AE; Ninteman FW; Serpa KA; Wiley JN; Wise LD; Heffner TG
    J Pharmacol Exp Ther; 1995 Aug; 274(2):912-20. PubMed ID: 7636754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437.
    Timmerman W; Tepper PG; Bohus BG; Horn AS
    Eur J Pharmacol; 1990 Jun; 181(3):253-60. PubMed ID: 1974516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
    Prinssen EP; Kleven MS; Koek W
    Eur J Pharmacol; 1998 Sep; 356(2-3):189-92. PubMed ID: 9774248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS; Joyce JN; Lucki I
    J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre- and postsynaptic actions of a partial D2 receptor agonist in reserpinized young rats: longevity of agonistic effects.
    Farley CM; Baella SA; Wacan JJ; Crawford CA; McDougall SA
    Brain Res; 2006 Dec; 1124(1):37-44. PubMed ID: 17070785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.